Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Innate Immunity
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1753425909105581v1
15/5/313    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Cerkovnik, P.
Right arrow Articles by Novakovic, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cerkovnik, P.
Right arrow Articles by Novakovic, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Class C CpG oligodeoxynucleotides as a single agent and in combination with radiotherapy efficiently delayed growth of subcutaneous B16F1 tumors

Petra Cerkovnik

Department of Molecular Diagnostics, Institute of Oncology Ljubljana, Ljubljana, Slovenia

Barbara Jezersek Novakovic

Division of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia,; snovakovic{at}onko-i.si

Vida Stegel

Department of Molecular Diagnostics, Institute of Oncology Ljubljana, Ljubljana, Slovenia

Srdjan Novakovic

Department of Molecular Diagnostics, Institute of Oncology Ljubljana, Ljubljana, Slovenia

Until now, the anti-tumor efficacy of synthetic oligodeoxynucleotides containing CpG motifs (CpG ODNs) has been reported in a number of preventive and therapeutic tumor models. Predominately class B CpG ODNs were used, relatively little has been reported regarding the class C CpG ODNs. The present study was, therefore, aimed at assessing the ability of CpG ODNs class C applied as a single agent and in combination with radiotherapy to induce the anti-tumor immunity in an experimental tumor model in mice (subcutaneous [s.c.] B16F1). Class C CpG ODNs applied three times as a single agent efficiently delayed the growth of s.c. B16F1 tumors. The combined therapy (CpG ODNs and tumor irradiation) remarkably enhanced the anti-tumor effect. The peritumoral (p.t.) application of CpG ODNs in combination with irradiation increased the number of dendritic cells (DCs) at the tumor site and improved the antigen loading and maturation of DCs. In conclusion, the combined therapy with CpG ODNs and irradiation creates a unique in situ DCs vaccine that could be easily applicable without prior knowledge of tumor antigens.

Key Words: CpG ODN • dendritic cells • innate immunity • radiotherapy • tumor vaccine

This version was published on October 1, 2009

Innate Immunity, Vol. 15, No. 5, 313-321 (2009)
DOI: 10.1177/1753425909105581
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?